Abstract
Guenther et al. have developed a protease-activatable AAV provector to target diseased tissue microenvironments exhibiting elevated extracellular protease activity. The provector delivers transgenes to high-MMP-activity regions of the damaged heart following a myocardial infarction, with concomitant decreased delivery to many off-target organs, including the liver.
Original language | English (US) |
---|---|
Pages (from-to) | 611-622 |
Number of pages | 12 |
Journal | Molecular Therapy |
Volume | 27 |
Issue number | 3 |
DOIs | |
State | Published - Mar 6 2019 |
Externally published | Yes |
Keywords
- AAV
- activatable
- adeno-associated virus
- cardiac gene therapy
- gene delivery
- gene therapy
- inflammation targeting
- matrix metalloproteinase
- myocardial infarction
- provector
- stimulus responsive
- viral vector
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
- Pharmacology
- Drug Discovery